Tumour surveillance: Missing peptides and MHC molecules
暂无分享,去创建一个
[1] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[2] F. Marincola,et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. , 1994, Journal of immunology.
[3] R. Doms,et al. Regulation of protein export from the endoplasmic reticulum. , 1988, Annual review of cell biology.
[4] R. Tampé,et al. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. , 1997, Experimental hematology.
[5] P. Kloetzel,et al. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12 , 1996, The Journal of experimental medicine.
[6] S. Beck,et al. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters , 1990, Nature.
[7] T. Schumacher,et al. Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[8] S. Steinberg,et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Rosenberg,et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Yewdell,et al. Trimming of antigenic peptides in an early secretory compartment , 1994, The Journal of experimental medicine.
[11] P. Robbins,et al. Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.
[12] B. Walker,et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. , 1993, Journal of immunology.
[13] S. Rosenberg,et al. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. , 1995, Journal of immunology.
[14] R. Tampé,et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. , 1997, Science.
[15] S. Rosenberg,et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. , 1996, Journal of immunology.
[16] M. Carrington,et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma , 1996, Hepatology.
[17] C. Slingluff,et al. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. , 1989, Journal of immunology.
[18] D J Moss,et al. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies , 1996, Journal of virology.
[19] A. Goldberg. Functions of the proteasome: the lysis at the end of the tunnel. , 1995, Science.
[20] C. Meijer,et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. , 1994, British Journal of Cancer.
[21] S. Rosenberg,et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. , 1995, Cancer research.
[22] G. Klein,et al. aberrant expression of HLA Class‐I antigens in burkitt lymphoma cells , 1991, International journal of cancer.
[23] P M Kloetzel,et al. Peptide antigen production by the proteasome: complexity provides efficiency. , 1996, Immunology today.
[24] P. Coulie,et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. Harris,et al. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. , 1995, Cancer research.
[26] R. Tampé,et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. , 1996, Cancer research.
[27] P. Romero,et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.
[28] S. Burrows,et al. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. , 1994, International immunology.
[29] J. Neefjes,et al. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling , 1994, The Journal of experimental medicine.
[30] S. Burrows,et al. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. , 1997, Journal of immunology.
[31] S. Ferrone,et al. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. , 1991, Cancer research.
[32] C. Meijer,et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas , 1994, The Journal of experimental medicine.
[33] R. Tampé,et al. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell‐mediated immune recognition of human melanoma cells , 1998, International journal of cancer.
[34] R. Siliciano,et al. An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL. , 1995, Journal of immunology.
[35] J. Trowsdale,et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expression , 1995, European journal of immunology.
[36] R. Linsk,et al. Histocompatibility antigens on murine tumors. , 1985, Science.
[37] J. Bryant,et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.
[38] P. Cresswell,et al. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. , 1997, Journal of immunology.
[39] M. Sanda,et al. Molecular characterization of defective antigen processing in human prostate cancer. , 1995, Journal of the National Cancer Institute.
[40] R. Tampé,et al. A sequential model for peptide binding and transport by the transporters associated with antigen processing. , 1994, Immunity.
[41] S. Rosenberg,et al. Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells , 1994, International journal of cancer.
[42] R. Brasseur,et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. , 1995, Immunity.
[43] H. Rammensee,et al. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA‐A2.1 , 1994, International journal of cancer.
[44] R. Henderson,et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. , 1992, Science.
[45] J. Yewdell,et al. Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.
[46] W. Bodmer,et al. MHC antigens and cancer: Implications for T-cell surveillance , 1992, Current Biology.
[47] F. Marincola,et al. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.
[48] R. Demars,et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway , 1990, Nature.
[49] A. Harris,et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. , 1994, The American journal of pathology.
[50] S. Ostrand-Rosenberg,et al. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. , 1991, Journal of immunology.
[51] Maria L. Wei,et al. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides , 1992, Nature.
[52] R. Siliciano,et al. Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells , 1993, Nature.
[53] P. Greenberg,et al. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. , 1986, Journal of immunology.